Kardiatec S.A. is a start-up company established in 2013. Our main focus is the manufacture and commercialization of PULVAD (Pressure Unloading Left Ventricular Assist Device), a cardiac device designed for patients suffering from end-stage heart failure.
Our team and main executives are: John Nanas (Emeritus Professor of Cardiology at the University of Athens), Jay W. Mason (Professor of Cardiology at the University of Utah) and Chris Mortis (biotechnologist).
Our initial capital for starting our company was privately funded.
The continuation of the company’s activities was supported by the financial aid of relatives and friends but also by our own funding and efforts.
Up until today, we have finished the manufacture and preclinical testing of PULVAD’s final model. Moreover, we have received authorization by the National Drug Organization (EOF) for conducting 2 clinical trials one of which is ongoing with very encouraging first indications.
Who we are
Our team and main executives are: John Nanas (Emeritus Professor of Cardiology at the University of Athens), Jay W. Mason (Professor of Cardiology at the University of Utah) and Chris Mortis (biotechnologist).
Dr. John Nanas
Emeritus Professor of Cardiology
Dr. Mason
Professor of Medicine (Cardiology)
Chris Mortis
CTO and founding member
